SCHEMBL20474240

SCHEMBL20474240

Cc1cccn2c(C3=NC(C)(C)C(F)(F)c4c(F)cccc43)cnc12

nearest known ligand 0.41

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 11/20 0.39
HDAC8 Q9BY41 1/20 0.34
TP53 P04637 3/20 0.32
PRMT5 O14744 1/20 0.32
WDR77 Q9BQA1 1/20 0.32
GABRA1 P14867 1/20 0.32
GABRG2 P18507 1/20 0.32
GABRB3 P28472 1/20 0.32
GABRA5 P31644 1/20 0.32
GABRA3 P34903 1/20 0.32
MAPT P10636 1/20 0.32
LMNA P02545 1/20 0.32
CACNA1B Q00975 1/20 0.32
APBA1 Q02410 1/20 0.32
TDP1 Q9NUW8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20474230 0.92 PRMT5 (0.38) IDO1PRMT5WDR77GABRA1GABRG2
SCHEMBL20474174 0.90 IDO1 (0.38) IDO1HDAC8TP53GABRA1GABRG2
SCHEMBL30829060 0.90 IDO1 (0.38) IDO1HDAC8TP53GABRA1GABRG2
SCHEMBL20474199 0.89 IDO1 (0.35) IDO1PRMT5WDR77GABRA1GABRG2
SCHEMBL18497913 0.86 IDO1 (0.33) IDO1HDAC8TP53MAPT
SCHEMBL30829058 0.86 IDO1 (0.33) IDO1HDAC8TP53MAPT
SCHEMBL20474212 0.81 IDO1 (0.35) IDO1PRMT5WDR77GABRA1GABRG2
SCHEMBL30829057 0.79 FLT1 (0.34) IDO1HDAC8TP53MAPT
SCHEMBL20474194 0.79 FLT1 (0.34) IDO1HDAC8TP53MAPT
SCHEMBL20474181 0.79 IDO1 (0.34) IDO1GABRA1GABRG2GABRB3GABRA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3929197-B1 INTERMEDIATES FOR THE SYNTHESIS OF MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2024-03-06 EP disclosed
EP-3334736-B1 MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2023-06-28 EP disclosed
EP-3929197-A1 INTERMEDIATES FOR THE SYNTHESIS OF MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2021-12-29 EP disclosed
US-20210155619-A1 MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2021-05-27 US disclosed
US-20210155619-A1 MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2021-05-27 US disclosed
US-10906897-B2 Microbiocidal heterobicyclic derivatives SYNGENTA PARTICIPATIONS AG (CH) 2021-02-02 US disclosed
US-10906897-B2 Microbiocidal heterobicyclic derivatives SYNGENTA PARTICIPATIONS AG (CH) 2021-02-02 US disclosed
US-20180237434-A1 MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2018-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10906897-B2 Microbiocidal heterobicyclic derivatives MSR1, C1R, C1S IDO1 175/4885HDAC8 3766/4885TP53 2048/4885
US-20210155619-A1 MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES CD14, MSR1, MPO IDO1 618/4885HDAC8 3254/4885TP53 2420/4885
US-20180237434-A1 MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES MSR1, C1R, C1S IDO1 175/4885HDAC8 3766/4885TP53 2048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.